<DOC>
	<DOCNO>NCT00621166</DOCNO>
	<brief_summary>To determine pharmacokinetic profile generic lopinavir/ritonavir tablet To investigate possible influence pregnancy duration pregnancy To determine antiviral activity safety generic lopinavir/ritonavirÂ® Compare pharmacokinetics parameter pregnancy .</brief_summary>
	<brief_title>Pharmacokinetics Generic Lopinavir/Ritonavir Pregnant Women</brief_title>
	<detailed_description>HAART pregnant HIV-infected serf two goal , prevent mother child transmission provide adequate treatment mother . Levels HIV RNA delivery use antiretrovirals ( ARV ) independently associate decreased transmission [ 1 ] . With HAART regimen transmission rate reduce till 2 % [ 1 , 2 ] . Possibly suitable drug use pregnancy lopinavir/ritonavir base regimen . In Thailand , aluvir available therefore generic lopinavir/ritonavir tablet formulation use study . In order prove adequate level lopinavir/ritonavir , record 12-hour PK third trimester . Second trim post-partum 12-hour PK optional . Furthermore , collect safety efficacy throughout study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Documented positive test HIV1 infection Subject least 18 old 40 year age day first dose study medication Subject able willing sign Informed Consent Form prior screen evaluation . Pregnant maximum 30 week day first dose study medication History sensitivity/idiosyncrasy drug chemically related compound excipients , may employ trial . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent trial procedure require . Abnormal serum transaminase creatinine , determined level &gt; 3 time upper limit normal . Concomitant use medication interfere Generic lopinavir/ritonavir pharmacokinetics Active hepatobiliary hepatic disease ( N.B . chronic hepatitis B/C coinfection allow ) Documented previous virological failure lopinavir/ritonavir contain regimen document resistance lopinavir/ritonavir prior dose</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Generic lopinavir/ritonavir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Antiviral activity</keyword>
	<keyword>Safety</keyword>
</DOC>